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patients with vaginal cancer and three with vulva cancer who 
received SBRT, either with radical or palliative intention. 
Conclusions: SBRT experience in gynecological tumours lacks 
homogeneity. Close to 400 patients treated with SBRT for 
locoregional disease were found in the literature and at least six 
different clinical scenarios were described. A high rate (> 20%) 
of late G3/4 GI toxicity was seen in patients with recurrent 
gynecological pelvic tumours when salvage was attempted with 
SBRT possibly due to multifactorial reasons. 
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Purpose: The ideal timing for post-implant dosimetry in 
permanent breast seed implant (PBSI) is yet unknown and is 
performed inconsistently across the country, limiting the ability 
to compare dosimetric indices among centres. The purpose of 
this study is to determine the most appropriate time to perform 
this post-implant analysis. 
Methods and Materials: Patients underwent four post-implant 
CT scans: 0, 15, 30, and 60 days after their seed implant. Each 
post-implant scan was deformably registered to the planning 
scan to obtain the seroma contour, which was reviewed and 
adjusted as necessary by a radiation oncologist. An evaluation 
PTV was defined to be a 5 mm isotropic expansion of the adjusted 
CTV contour, trimmed to the chest wall muscle and skin. 
Standard post-plans using the TG-43 calculation formalism were 
completed on each scan, considering dosimetric parameters for 
the CTV (V100) and evaluation PTV (V90, V100, and V200). As a 
reference, accumulated dose was determined by deformably 
summing the dose from all four time points to the day 0 post-
implant scan, taking into account the decay of the seeds to 
weight the dosimetric contribution from each time point. Each 
time point was compared to the reference accumulated dose by 
sum-of-squared residuals and absolute differences for each 
dosimetric index. 
Results: Five patients have completed all four post-implant CT 
scans. The PTV V200 showed the most significant disagreement 
between the accumulated dose and each individual postplan 
(median absolute disagreement: 7.3%, range: 0.7 – 16.8%), while 
the CTV V100 showed fairly consistent agreement for all time 
points (median absolute disagreement: 0.5%, range: 0.0 – 5.3%). 
The day 15 scan showed the smallest sum-of-squared residuals 
for both the CTV V100 and the PTV V200; 51% and 52% lower than 
the next best time point, respectively, when considering the 
entire cohort. Other time points, however, still showed similar 
CTV V100 values, while other dosimetric indices had more 
variation in both time and between individual patients. 
Conclusions: For the five patients who have completed all four 
requisite scans, the PTV V200 showed the largest variation when 
compared to the reference accumulated dose, while the CTV 
V100 had fairly good agreement for all time points. The time 
point which best agrees with the reference accumulated dose is 
not unanimous for all patients; further patient accrual is ongoing 
and required to recommend the most appropriate time point for 
the population. 
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Purpose: At the Allan Blair Cancer Centre, we began real-time 
ultrasound-guided prostate HDR on May 13, 2015. Starting with 
our third case, we began monitoring various time points during 
the procedure to see how long different parts took and whether 
there was reduction in times as the number of cases increased. 
Methods and Materials: Several time points were recorded for 
each case including the "Time Out" before anesthetic induction, 
TRUS insertion, placement of first needle, start of contouring, 
start of needle reconstruction, start of plan QA, start of 
treatment and start of needle removal. The experience in 
number of cases performed by each team member was also 
monitored. Members involved over the period of study included 
three physicists, four radiation therapists, three radiation 
oncologists and five radiation therapy nurses as well as a number 
of anesthesiologists from the health region. Treatment planning 
was performed by two physicists and two radiation therapists. 
Results: For cases 3 to 27, the average overall time from "Time 
Out" to catheter removal was 3 hours 45 minutes. The longest 
part of the process was for needle reconstruction and treatment 
planning, with an average time of 1 hour 9 minutes. Using a linear 
fit to the data for these 25 consecutive cases, the overall time 
decreased by 21 minutes, or about 9%. This is primarily due to a 
decrease of 17 minutes in needle reconstruction and planning 
time and a decrease of seven minutes in anesthetic induction 
time. The trends for other times varied by less than four minutes. 
Discussion: We observed a significant decrease in the time for 
needle reconstruction and treatment planning with the number 
of cases performed. This is likely due to increased familiarity 
with the planning system and looking at ultrasound images as 
well as improved needle placement preventing shadowing of one 
needle by another. The reason for the decrease in anesthetic 
induction time is likely better preparation (making sure the carts 
are functioning and stocked and calling for an endotracheal 
scope early in cases that might require one). These are important 
factors when doing anesthetic procedures outside the OR with 
many different anesthesiologists. 
Conclusions: Over 25 consecutive cases, we saw a decrease in 
total time for real-time ultrasound-guided prostate HDR of 9%, 
with the largest factor being a decrease in the time for needle 
reconstruction and treatment planning. We will continue to 
monitor our process and will also look at correlating times with 
the experience levels of individual team members. 
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Purpose: To evaluate biochemical disease-free survival rates and 
toxicity in patients treated with combined EBRT and HDR 
brachytherapy boost. 
Methods and Materials: We reviewed data for men with prostate 
cancer treated with EBRT and brachytherapy boost from 2010 to 
2014 in one centre. From 2010-2012 patients were treated with 
50 Gy in 20 fractions of EBRT with a 10Gy HDR boost. From 2012-
2014 patients were treated with 44 Gy in 22 fractions of EBRT 
and 15 Gy EBRT boost. From 2014 onwards 37.5 Gy in 15 fractions 
combined with 15 Gy brachytherapy boost was used. 
Results: One hundred and sixty-five consecutive patients treated 
from 2010 to 2014 were evaluated. Median age was 67. 4% (n = 
6) had low-risk prostate cancer, 76% (n = 125) had intermediate-
risk and 20% (n=34) had high-risk disease. Twenty-seven percent 
(n = 44) received 50 Gy+10 Gy boost, 49% (n = 81) received 44 Gy 
+ 15 Gy boost and 24% (n = 40) received 37.5 Gy + 15 Gy boost. 
Fifty percent had brachytherapy prior to EBRT and the other 50% 
had brachytherapy after EBRT. Thirty-five percent received 
androgen deprivation therapy. Actuarial Biochemical Disease-
Free Survival (Phoenix definition) was 89% at five years (100%, 
87% and 100% respectively for low-, intermediate- and high-risk). 
